Data Integrity Inspections Go Global
This article was originally published in The Gold Sheet
Executive Summary
As FDA and other regulatory authorities throughout the world learn how to conduct the type of inspections that have put a spotlight on data integrity failures in India, they are warning that no manufacturer, no matter how sophisticated they are, no matter where they’re located, is immune from this potentially devastating issue.
You may also be interested in...
Key Senator Hinges Support For Cheap Drug Imports On Surprise Inspections
More unannounced inspections abroad would warm Senate Finance Committee chairman to President Trump's drug importation plan.
FDA Warning Letter Could Impact Zhejiang Medicine’s US Foray
Zhejiang Medicine has become the latest major Chinese API firm to be hit with a US FDA warning letter amid stepped up oversight of production facilities in China by the US regulator, which has led to a string of similar actions this year alone. But efforts are now being made both by Chinese manufacturers and by authorities in the two countries to ensure adherence to international standards.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.